Effectiveness of oseltamivir in adults: A meta-analysis of published and unpublished clinical trials

Mark H. Ebell, Marlene Williamson Call, Jo Anna Shinholser

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Background. Oseltamivir is widely used for the treatment of influenza. Previous systematic reviews suggest that they reduce complications, but had significant methodologic limitations. Objective. To assess the effect of oseltamivir on duration of symptoms, complications and hospitalizations in adults. Methods. We searched Medline without time or language restrictions, and trial registries maintained by the manufacturer. We included published and unpublished randomized double-blinded, placebo-controlled trials of oseltamivir in adults with suspected influenza that reported duration of symptoms, complications or hospitalizations. We abstracted data regarding study quality, the duration of symptoms and rates of complications and hospitalization. Results. Three published and eight unpublished studies met our inclusion criteria. For the intention- to-treat (ITT) population, the mean reduction in the duration of symptoms was 20.7 hours [95% confidence interval (CI) 13.3 to 28.0 hours]. Two large unpublished studies in the elderly and in adults with chronic disease did not find a significant reduction in the symptom duration. There was no difference in the likelihood of hospitalization in the ITT population (33/2633 patients for oseltamivir versus 20/1694 for placebo). The rate of complications in the intention-to-treat infected (ITTI) population was reduced when acute bronchitis was included (-2.8%, 95% CI -0.6 to -4.9), but not when it was excluded. The risk of pneumonia was reduced in the ITTI population (-0.9%, 95% CI -0.1 to -1.7) but not in the ITT population. Conclusions. There is no evidence that oseltamivir reduces the likelihood of hospitalization, pneumonia or the combined outcome of pneumonia, otitis media and sinusitis in the ITT population.

Original languageEnglish (US)
Pages (from-to)125-133
Number of pages9
JournalFamily Practice
Volume30
Issue number2
DOIs
StatePublished - Apr 1 2013

Fingerprint

Oseltamivir
Meta-Analysis
Clinical Trials
Hospitalization
Population
Pneumonia
Confidence Intervals
Human Influenza
Placebos
Bronchitis
Sinusitis
Otitis Media
Registries
Chronic Disease
Language

Keywords

  • Hospitalization
  • Influenza
  • Meta-analysis
  • Oseltamivir
  • Systematic review

ASJC Scopus subject areas

  • Family Practice

Cite this

Effectiveness of oseltamivir in adults : A meta-analysis of published and unpublished clinical trials. / Ebell, Mark H.; Call, Marlene Williamson; Shinholser, Jo Anna.

In: Family Practice, Vol. 30, No. 2, 01.04.2013, p. 125-133.

Research output: Contribution to journalReview article

@article{5d3910d2e62e469d95898990f027cd69,
title = "Effectiveness of oseltamivir in adults: A meta-analysis of published and unpublished clinical trials",
abstract = "Background. Oseltamivir is widely used for the treatment of influenza. Previous systematic reviews suggest that they reduce complications, but had significant methodologic limitations. Objective. To assess the effect of oseltamivir on duration of symptoms, complications and hospitalizations in adults. Methods. We searched Medline without time or language restrictions, and trial registries maintained by the manufacturer. We included published and unpublished randomized double-blinded, placebo-controlled trials of oseltamivir in adults with suspected influenza that reported duration of symptoms, complications or hospitalizations. We abstracted data regarding study quality, the duration of symptoms and rates of complications and hospitalization. Results. Three published and eight unpublished studies met our inclusion criteria. For the intention- to-treat (ITT) population, the mean reduction in the duration of symptoms was 20.7 hours [95{\%} confidence interval (CI) 13.3 to 28.0 hours]. Two large unpublished studies in the elderly and in adults with chronic disease did not find a significant reduction in the symptom duration. There was no difference in the likelihood of hospitalization in the ITT population (33/2633 patients for oseltamivir versus 20/1694 for placebo). The rate of complications in the intention-to-treat infected (ITTI) population was reduced when acute bronchitis was included (-2.8{\%}, 95{\%} CI -0.6 to -4.9), but not when it was excluded. The risk of pneumonia was reduced in the ITTI population (-0.9{\%}, 95{\%} CI -0.1 to -1.7) but not in the ITT population. Conclusions. There is no evidence that oseltamivir reduces the likelihood of hospitalization, pneumonia or the combined outcome of pneumonia, otitis media and sinusitis in the ITT population.",
keywords = "Hospitalization, Influenza, Meta-analysis, Oseltamivir, Systematic review",
author = "Ebell, {Mark H.} and Call, {Marlene Williamson} and Shinholser, {Jo Anna}",
year = "2013",
month = "4",
day = "1",
doi = "10.1093/fampra/cms059",
language = "English (US)",
volume = "30",
pages = "125--133",
journal = "Family Practice",
issn = "0263-2136",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Effectiveness of oseltamivir in adults

T2 - A meta-analysis of published and unpublished clinical trials

AU - Ebell, Mark H.

AU - Call, Marlene Williamson

AU - Shinholser, Jo Anna

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Background. Oseltamivir is widely used for the treatment of influenza. Previous systematic reviews suggest that they reduce complications, but had significant methodologic limitations. Objective. To assess the effect of oseltamivir on duration of symptoms, complications and hospitalizations in adults. Methods. We searched Medline without time or language restrictions, and trial registries maintained by the manufacturer. We included published and unpublished randomized double-blinded, placebo-controlled trials of oseltamivir in adults with suspected influenza that reported duration of symptoms, complications or hospitalizations. We abstracted data regarding study quality, the duration of symptoms and rates of complications and hospitalization. Results. Three published and eight unpublished studies met our inclusion criteria. For the intention- to-treat (ITT) population, the mean reduction in the duration of symptoms was 20.7 hours [95% confidence interval (CI) 13.3 to 28.0 hours]. Two large unpublished studies in the elderly and in adults with chronic disease did not find a significant reduction in the symptom duration. There was no difference in the likelihood of hospitalization in the ITT population (33/2633 patients for oseltamivir versus 20/1694 for placebo). The rate of complications in the intention-to-treat infected (ITTI) population was reduced when acute bronchitis was included (-2.8%, 95% CI -0.6 to -4.9), but not when it was excluded. The risk of pneumonia was reduced in the ITTI population (-0.9%, 95% CI -0.1 to -1.7) but not in the ITT population. Conclusions. There is no evidence that oseltamivir reduces the likelihood of hospitalization, pneumonia or the combined outcome of pneumonia, otitis media and sinusitis in the ITT population.

AB - Background. Oseltamivir is widely used for the treatment of influenza. Previous systematic reviews suggest that they reduce complications, but had significant methodologic limitations. Objective. To assess the effect of oseltamivir on duration of symptoms, complications and hospitalizations in adults. Methods. We searched Medline without time or language restrictions, and trial registries maintained by the manufacturer. We included published and unpublished randomized double-blinded, placebo-controlled trials of oseltamivir in adults with suspected influenza that reported duration of symptoms, complications or hospitalizations. We abstracted data regarding study quality, the duration of symptoms and rates of complications and hospitalization. Results. Three published and eight unpublished studies met our inclusion criteria. For the intention- to-treat (ITT) population, the mean reduction in the duration of symptoms was 20.7 hours [95% confidence interval (CI) 13.3 to 28.0 hours]. Two large unpublished studies in the elderly and in adults with chronic disease did not find a significant reduction in the symptom duration. There was no difference in the likelihood of hospitalization in the ITT population (33/2633 patients for oseltamivir versus 20/1694 for placebo). The rate of complications in the intention-to-treat infected (ITTI) population was reduced when acute bronchitis was included (-2.8%, 95% CI -0.6 to -4.9), but not when it was excluded. The risk of pneumonia was reduced in the ITTI population (-0.9%, 95% CI -0.1 to -1.7) but not in the ITT population. Conclusions. There is no evidence that oseltamivir reduces the likelihood of hospitalization, pneumonia or the combined outcome of pneumonia, otitis media and sinusitis in the ITT population.

KW - Hospitalization

KW - Influenza

KW - Meta-analysis

KW - Oseltamivir

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84875580020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875580020&partnerID=8YFLogxK

U2 - 10.1093/fampra/cms059

DO - 10.1093/fampra/cms059

M3 - Review article

C2 - 22997224

AN - SCOPUS:84875580020

VL - 30

SP - 125

EP - 133

JO - Family Practice

JF - Family Practice

SN - 0263-2136

IS - 2

ER -